IL-13-PE38QQR
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for IL-13-PE38QQR, covering 2018-07-05 to 2018-07-05. Get the full timeline:
Most recent: Clinical Trial Update: An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma [Phase 1]